Cancer incidence and mortality patterns in Europe: estimates for, vol.40 ,
, Eur J Cancer Oxf Engl, vol.49, issue.6, pp.1374-403, 1990.
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification, J Thorac Oncol. 1 sept, vol.10, issue.9, pp.1243-60, 2015. ,
The Eighth Edition Lung Cancer Stage Classification, Chest. janv, vol.151, issue.1, pp.193-203, 2017. ,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.16, issue.20, pp.1919-1948, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer ,
, N Engl J Med, vol.10, pp.1823-1856, 2016.
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol. janv, vol.11, issue.1, pp.39-51, 2016. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview, Curr Oncol. 14 juin, vol.25, issue.0, pp.77-85, 2018. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. 22 mars, vol.12, issue.4, pp.252-64, 2012. ,
Immunologic and clinical effects of targeting PD-1 in lung cancer, Clin Pharmacol Ther. août, vol.96, issue.2, pp.214-237, 2014. ,
,
, Cancer Radiother J Soc Francaise Radiother Oncol. mai, vol.21, issue.3, pp.244-55, 2017.
Role of Local Radiation Therapy in Cancer Immunotherapy, JAMA Oncol. déc, vol.1, issue.9, pp.1325-1357, 2015. ,
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade, Cancer Res, vol.74, pp.5458-68, 2014. ,
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.15, issue.17, pp.5379-88, 2009. ,
PD-1 Restrains Radiotherapy-Induced Abscopal Effect, Cancer Immunol Res. juin, vol.3, issue.6, pp.610-619, 2015. ,
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant, Cancer Treat Rev. juin, vol.41, issue.6, pp.503-513, 2015. ,
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. avr, vol.13, issue.4, pp.510-530, 2018. ,
Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues, Int J Radiat Oncol ? Biol ? Phys. 1 déc, vol.99, issue.5, pp.1129-1165, 2017. ,
Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med. 8 mars, vol.366, issue.10, pp.925-956, 2012. ,
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors, Invest New Drugs, vol.35, issue.2, pp.207-223, 2017. ,
Estimation du bénéfice de survie à partir de méta-analyse sur données individuelles et évaluation économique, 2016. ,
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol Off J Am Soc Clin Oncol, 2017. ,
Concurrent radiotherapy for patients with metastatic melanoma and receiving antiprogrammed-death 1 therapy: a safe and effective combination, Melanoma Res, vol.27, issue.5, pp.485-91, 2017. ,
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma, Oncoimmunology, vol.5, issue.9, p.1214788, 2016. ,
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol Off J Eur Soc Med Oncol. mars, vol.27, issue.3, pp.434-475, 2016. ,
Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy, Int J Radiat Oncol ? Biol ? Phys. 1 juin, vol.98, issue.2, pp.344-51, 2017. ,
Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy, JAMA Oncol, 2017. ,
Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer, J Thorac Oncol, vol.5, issue.2018 ,
,
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 déc, vol.35, issue.34, pp.3815-3837, 2017. ,
Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center, Cancer Immunol Res. 30 janv, 2018. ,
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J Clin Oncol Off J Am Soc Clin Oncol. mars, vol.35, issue.7, pp.785-92, 2017. ,
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol. juill, vol.18, issue.7, pp.895-903, 2017. ,
Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study, Ann Oncol Off J Eur Soc Med Oncol. 20 mars, 2017. ,
Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?, Br J Radiol ,
Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab, Int J Radiat Oncol Biol Phys, vol.01, issue.1, pp.72-79, 2016. ,
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment, Int J Radiat Oncol Biol Phys. 1 juin, vol.92, issue.2, pp.368-75, 2015. ,